Senetek PLC Announces Voting Results From Its Annual General Meeting Monday December 10, 4:00 pm ET
NAPA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNTKY - News), a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics, today announced that shareholders had approved all seven resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 10, 2007. ADVERTISEMENT
"We are pleased with the results of the voting and we thank our shareholders for their support," stated Frank J. Massino, Senetek CEO. "The Board and management of Senetek are looking forward to 2008, as we move ahead with several exciting business opportunities in the coming year."
About Senetek PLC
Senetek PLC (OTCBB: SNTKY - News) is a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics. Senetek recently announced a Marketing Collaboration Agreement for its second-generation cytokinin with Triax Aesthetics LLC which will guarantee a minimum of $10.8 million in revenues in 2008 and granted Valeant Pharmaceuticals a paid up license for Senetek's first generation patented skin care active ingredient Kinetin and its analog Zeatin in return for $21 million cash and forgiveness of $6 million prepaid royalty credit, and is negotiating third party license agreements for new patent-pending second generation dermatological active ingredients and is completing development of a number of additional compounds. In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for Invicorp®, has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject®.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.